Roche scores its first PD-L1 win in Chi­na, go­ing straight for SCLC niche

6 years ago
China
Pharma

Af­ter FDA hold and tri­al fail­ure, Ipsen writes down its big ac­qui­si­tion — but they're not giv­ing up

6 years ago
Pharma

Bris­tol-My­ers checks off an­oth­er mile­stone on the Cel­gene CVR, hus­tling Yescar­ta ri­val to the mar­ket

6 years ago
R&D

Af­ter years of busi­ness and law­suit-fu­eled de­cline, is a Te­va turn­around in sight?

6 years ago
Pharma

De­ci­pher­a's GIST ther­a­py ripretinib wins speedy FDA re­view — set­ting the stage for bat­tle with ri­val Blue­print

6 years ago
FDA+

The RAS rush: Rev­o­lu­tion Med­i­cines bags re­mark­able $238M IPO raise, more than dou­bling orig­i­nal goal

6 years ago
Financing

Pre­vail's gene ther­a­py scores or­phan, rare pe­di­atric dis­ease priv­i­leges; Ger­many's ITM se­cures €40M loan

6 years ago
News Briefing

No­var­tis chris­tens new UK HQ in West Lon­don, kick­ing off its big in­clisir­an CV tri­al

6 years ago
People
R&D

Coro­n­avirus up­date: A sum­mit in Gene­va, WuXi hunts an­ti­bod­ies and J&J part­ners on a vac­cine search

6 years ago
R&D
Coronavirus

Corey Good­man mar­shals $105M mega-round for his CD47 up­start, look­ing to break new ground in PhII

6 years ago
Financing
Startups

Catch­ing up with Roche, Mer­ck racks up pos­i­tive da­ta in front­line triple neg­a­tive breast can­cer

6 years ago
R&D
Pharma

New Sanofi chief Paul Hud­son takes the ax to his ex­ec­u­tive com­mit­tee, chop­ping 4 key play­ers

6 years ago
R&D

Lil­ly, No­vo Nordisk fight in­sulin biosim­i­lars with tweaks to FDA draft guid­ance

6 years ago
Pharma
FDA+

Eas­ing con­cerns, Fi­bro­Gen, As­traZeneca se­cure FDA date for their ane­mia drug in broad chron­ic kid­ney dis­ease ...

6 years ago
R&D
FDA+

Lig­and buys its way in­to part­ner­ship with Roche, CF Foun­da­tion — plus some ion chan­nel tech once owned by Pfiz­er

6 years ago
Deals

Bay­er hands over a big drug R&D op­er­a­tion to CRO amid an on­go­ing re­struc­tur­ing ef­fort

6 years ago
Deals
R&D

A Chi­nese com­pa­ny is al­ready mass pro­duc­ing Gilead­'s ex­per­i­men­tal coro­n­avirus drug

6 years ago
China
Coronavirus

The Wuhan coro­n­avirus has an of­fi­cial name: COVID-19; Rev­o­lu­tion Med­i­cines up­sizes IPO terms

6 years ago
News Briefing
Coronavirus

Agios' Lewis Cant­ley re­turns with a new com­pa­ny and, he claims, a ma­jor on­co­log­i­cal dis­cov­ery

6 years ago
R&D

Pfiz­er un­cou­ples from Gly­coMimet­ics and its failed sick­le cell dis­ease drug

6 years ago
Deals
R&D

No­var­tis nabs pri­or­i­ty re­view for a block­buster-to-be aimed at NSCLC niche — de­light­ing In­cyte ex­ecs

6 years ago
FDA+

Up­start can­cer biotech re­cruits a top Pfiz­er on­col­o­gy re­searcher as CSO — could an IPO be far be­hind?

6 years ago
R&D

Mer­ck-al­lied Seat­tle Ge­net­ics’ pos­i­tive up­date on its 2nd ADC may point to an ac­cel­er­at­ed dash to the FDA fin­ish ...

6 years ago
R&D

Mod­er­na eyes $500M sec­ondary of­fer­ing on up­beat coro­n­avirus vac­cine up­date — al­most ready for the clin­ic

6 years ago
Deals
Coronavirus
First page Previous page 854855856857858859860 Next page Last page
A service from the Financial Times